RT Journal Article
SR Electronic
T1 Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021 – January 2022: a retrospective, population-based, matched cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.02.22269952
DO 10.1101/2022.02.02.22269952
A1 Auvigne, Vincent
A1 Vaux, Sophie
A1 Le Strat, Yann
A1 Schaeffer, Justine
A1 Fournier, Lucie
A1 Tamandjou, Cynthia
A1 Montagnat, Charline
A1 Coignard, Bruno
A1 Levy-Bruhl, Daniel
A1 du Châtelet, Isabelle Parent
YR 2022
UL http://medrxiv.org/content/early/2022/03/07/2022.02.02.22269952.abstract
AB Background A rapid increase in incidence of the SARS-CoV-2 Omicron variant occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta.Methods We conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model.Findings Between 06/12/2021-28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (aHR=0·11 95%CI: 0·07-0·17 among 40-64 years, aHR=0·51 95%CI: 0·26-1·01 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·18 95%CI: 2·88-6·06 among 40-64 years) and in males (aHR=2·29 95%CI: 1·83-2·86 among 40-64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=6·90 95%CI: 5·26-9·05 among 40-64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·27; 95%CI: 0·11-0·65).Interpretation This study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was performed as part of routine work at Public Health France.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of Public Health France waived ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWhile all data used in this analysis were pseudonymised, the individual-level nature of the data used risks individuals being identified, or being able to self-identify, if it is released publicly. Requests for access to the underlying source data should be directed to Public Health France and will be granted in accordance with the GDPR and French Law.